IL-21 alleviates allergic asthma in DOCK8-knockout mice
Creators
- 1. Pediatric Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Children's Hospital of Chongqing Medical University, Chongqing, 400014 (China)
- 2. Pediatric Department, Central Hospital of Enshi Autonomous Prefecture, Hubei, 445000 (China)
- 3. Department of Infectious Diseases, Children's Hospital of Chongqing Medical University, Chongqing, 400014 (China)
- 4. Department of Dermatology, Children's Hospital of Chongqing Medical University, Chongqing, 400014 (China)
- 5. Department of Immunology, Children's Hospital of Chongqing Medical University, Chongqing, 400014 (China)
- 6. Department of Respiratory Diseases, Children's Hospital of Chongqing Medical University, Chongqing, 400014 (China)
Description
Highlights: • DOCK8-KO mice induced by 5 μg of OVA showed markedly allergic asthma. • Nasal administration of rmIL-21 alleviates allergic asthma in KO-OVA mice. • IL-21 administration reduced IgE production in DOCK8-KO mice. Patients with DOCK8 deficiency are at increased susceptibility to develop allergic diseases such as food allergy and asthma. Here, we aimed to analyze the pathogenesis of asthma in DOCK8-deficient patients. In our mouse model, DOCK8-knockout (KO) mice sensitized with low-dose OVA were challenged with 1.5% OVA to induce allergic asthma. As compared to that in WT mice, remarkable airway hyperresponsiveness was observed in KO mice. Increased inflammatory cells and eosinophils infiltrated in airway lumen in KO mice especially around bronchi. KO mice showed higher levels of serum IgE and OVA-specific IgE and significantly elevated IgE-producing B cells in blood and in spleen. Surprisingly, nasal administration with rmIL-21 significantly reduced the airway hyperresponsiveness, inflammatory infiltration, as well as the serum IgE and IgE-producing B cells. DOCK8-knockout mice are susceptible to low-dose OVA induced allergic airway inflammation and airway hyperresponsiveness. Supplementary nasal administration of rmIL-21 alleviates allergic asthma in this mouse model.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.bbrc.2018.04.179Additional details
Identifiers
- DOI
- 10.1016/j.bbrc.2018.04.179;
- PII
- S0006291X18309720;
Publishing Information
- Journal Title
- Biochemical and Biophysical Research Communications
- Journal Volume
- 501
- Journal Issue
- 1
- Journal Page Range
- p. 92-99
- ISSN
- 0006-291X
- CODEN
- BBRCA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 53054300
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- ASTHMA; BRONCHI; EOSINOPHILS; INFLAMMATION; MICE
- Descriptors DEC
- ANIMALS; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY FLUIDS; DISEASES; LEUKOCYTES; MAMMALS; MATERIALS; PATHOLOGICAL CHANGES; RESPIRATORY SYSTEM; RESPIRATORY SYSTEM DISEASES; RODENTS; SYMPTOMS; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2018 Elsevier Inc. All rights reserved.